F-star's Delayed Acquisition Presents A Risky Opportunity
F-star Therapeutics: A Merger Arbitrage Opportunity Expected To Close Soon
New Strong Buy Stocks for July 15th
F-star (FSTX) Stock Rises on Buyout Offer From Sino Biopharm
F-star Therapeutics Shares Are Rallying Today - Read Why
Fstar Therapeutics, Inc. (FSTX) Reports Q1 Loss, Tops Revenue Estimates
Fstar Therapeutics, Inc. (FSTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
F-Star Therapeutics, Inc. (FSTX) CEO Eliot Forster On Q4 2021 Results - Earnings Call Transcript
F-star Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference
F-star Therapeutics to Host Fourth Quarter and Full-Year 2021 Financial Results Conference Call on March 14, 2022
F-star Therapeutics: Best-In-Class Tetravalent Bispecific Antibody Technology In Cancers
F-star Therapeutics to Participate in Upcoming Investor Conferences
F-star Therapeutics to Present FS222 Trial-in-Progress Update at ESMO Immuno-Oncology Congress 2021
F-star Therapeutics (FSTX) Sees Hammer Chart Pattern: Time to Buy?
F-star Therapeutics, Inc. (FSTX) CEO Eliot Forster on Q3 2021 Results - Earnings Call Transcript
F-star Therapeutics to Present at The Society for Immunotherapy of Cancer (SITC) 2021 Conference
F-star Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference
F-star Therapeutics, Inc. (FSTX) CEO Eliot Forster on Q2 2021 Results - Earnings Call Transcript
Why F-star Therapeutics (FSTX) Might Surprise This Earnings Season
5 Drug/Biotech Stocks Set to Outpace Q2 Earnings Estimates
F-star Therapeutics to Announce Second Quarter Results and Host Conference Call on August 12, 2021
F-star Therapeutics Provides Interim Update on SB 11285 First-In-Human Dose-Escalation Study in Patients with Advanced Solid Tumors
F-star Therapeutics to Present at Upcoming Investor Conferences
IONTAS Collaboration With F-star Enters Oncology Phase 1 Clinical Trial
Week 25 MDA Breakout Stocks - June 2021: Short-Term Picks To Give You An Edge
F-star Therapeutics, Inc. (FSTX) CEO Eliot Forster on Q1 2021 Results - Earnings Call Transcript
F-star Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
Study Published in Nature Shows F-Star's STING Agonist SB 11285 Enhances Preclinical Efficacy of Radiation Therapy
F-star Therapeutics Shows Differentiation of FS222 in 2021 AACR Poster
FSTX Stock Price Increased Over 5% Pre-Market: Why It Happened
FSTX Stock Price Increased Over 34% Intraday: Why It Happened
Why Cellect, Immutep, F-star, ProQR and Evofem Are Moving Thursday
F-star Therapeutics to Present at Upcoming Investor Conferences
FSTX Stock Price Increases Over 25% Pre-Market: Why It Happened
F-star Therapeutics: New Biologics Platform For Immunotherapy
F-star Granted Composition of Matter Patent for FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1
F-star Therapeutics Announces First Patient Dosed in FS222 Phase 1 Clinical Trial